Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Norton

Showing results (131-140 of 293) with videos related to

Pageof 30
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancerMonica N Fornier, Andrew D Seidman, Diana Lake, et al.
Breast Cancer Research and Treatment|April 2, 2005
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerShanu Modi, Andrew D Seidman, Maura Dickler, et al.
Cancer|October 21, 2004
A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapyMichael W Kattan, Dilip Giri, Katherine S Panageas, et al.
Genome Biology|October 29, 2014
Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutationsLuciano G Martelotto, Charlotte Ky Ng, Maria R De Filippo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancersSarat Chandarlapaty, Ayana Sawai, Qing Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2019
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System MetastasesAki Morikawa, Elisa de Stanchina, Elena Pentsova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group BRaymond B Weiss, Susan H Woolf, Erin Demakos, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 4, 2015
Corrigendum: metastatic breast carcinomas display genomic and transcriptomic heterogeneityBritta Weigelt, Charlotte K Y Ng, Ronglai Shen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2014
Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. Britta Weigelt, Charlotte K Y Ng, Ronglai Shen, et al.
Clinical Breast Cancer|July 9, 2013
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancerAndrew D Seidman, Alison K Conlin, Ariadne Bach, et al.
Pageof 30

Showing results (131-140 of 293) with videos related to

Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancerMonica N Fornier, Andrew D Seidman, Diana Lake, et al.
Breast Cancer Research and Treatment|April 2, 2005
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerShanu Modi, Andrew D Seidman, Maura Dickler, et al.
Cancer|October 21, 2004
A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapyMichael W Kattan, Dilip Giri, Katherine S Panageas, et al.
Genome Biology|October 29, 2014
Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutationsLuciano G Martelotto, Charlotte Ky Ng, Maria R De Filippo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancersSarat Chandarlapaty, Ayana Sawai, Qing Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2019
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System MetastasesAki Morikawa, Elisa de Stanchina, Elena Pentsova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group BRaymond B Weiss, Susan H Woolf, Erin Demakos, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 4, 2015
Corrigendum: metastatic breast carcinomas display genomic and transcriptomic heterogeneityBritta Weigelt, Charlotte K Y Ng, Ronglai Shen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2014
Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. Britta Weigelt, Charlotte K Y Ng, Ronglai Shen, et al.
Clinical Breast Cancer|July 9, 2013
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancerAndrew D Seidman, Alison K Conlin, Ariadne Bach, et al.
Pageof 30